Video Series

Drs Chitre and Weaver explore social and health care disparities more prominently affecting various MDD patient populations.

Expert panelists share strategies and considerations for selecting optimal treatment pathways for patients with lupus nephritis.

Alvin Wells, MD, PhD, provides an overview of the lupus nephritis treatment landscape.

The role of combination therapy is explored for the treatment of COPD.

Social determinants of health (SDoH) can create major barriers for access to care.

An expert discusses the current treatment landscape of Rett syndrome including the goals of treatment and implications for utilization management strategies with the disease.

David Lieberman, MD, PhD, reviews the economic burden and long-term complications of Rett syndrome as well as highlights the unmet needs for patients.

James Cleary, MD, PhD, and Laura Bobolts, PharmD, BCOP, highlight new GI and esophageal cancer therapies and their positive impacts on their patient population.

James M. Cleary, MD, PhD, discusses chemotherapy and immunotherapy as appropriate individual strategies, as well as a combination therapy approach for patients with gastroesophageal cancer.

Payers provide insights to health care disparities currently impacting patients with major depressive disorder (MDD).

Jay Weaver, PharmD, MPH, and Mona Chitre, PharmD, CGP, discuss the increased demand for mental health services since the COVID-19 pandemic.

Alvin Wells, MD, PhD, and Jorge Larranaga, MD, highlight the goals of treatment for patients with lupus nephritis.

Key opinion leaders discuss aspects driving care pathways for patients with lupus nephritis.

Social and economic burdens affecting patients with COPD provide significant obstacles to optimizing care.

Jeffrey D. Dunn, PharmD, MBA, leads a panel discussion on disease and treatment landscapes for COPD.

An expert explains how Rett syndrome is diagnosed, how commonly it is misdiagnosed, disease progression, and which providers are best positioned to manage a Rett Syndrome patient.

David Lieberman, MD, PhD, describes Rett syndrome, including the various stages, incidence, and potential causes of this disease.

In a sign that value-based care is here to stay, some practices that did not participate in the Oncology Care Model (OCM) have applied for the Enhancing Oncology Model (EOM).

The Center for Medicare and Medicaid Innovation (CMMI) was a strong collaborator during the Oncology Care Mode (OCM), but the timing of the Enhancing Oncology Model came as a surprise.

Dr Cleary outlines strategies to individualize care for patients diagnosed with upper GI and esophageal cancer.

Laura Bobolts, PharmD, BCOP, and James M. Cleary, MD, provide insights regarding gastroesophageal treatment decisions when FDA labels don’t reflect clinical practice guidelines.

Key social determinants affecting MDD are evaluated by Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP.

Expert panelists explore prevalence and disparities of MDD across patient populations.

Jorge Larranaga, MD, provides his opinion regarding the criticality of urgency in LN treatment.

Jorge Larranaga, MD, and Alvin Wells, MD, PhD, describe the progression of SLE to lupus nephritis.

Immune checkpoint inhibitors can play a key role in the treatment of upper-GI and esophageal cancer.

Key opinion leaders navigate unmet needs across the treatment landscape of gastroesophageal cancer.

Managed care experts discuss health disparities among various patient populations affected by MDD.

Drs Cannon and Rothrock provide insights into their process for defining value among newly launched MDD treatments.

Experts from US Oncology, Tennessee Oncology, AON, and COA dig into the details of implementing the Enhancing Oncology Model, set to take effect July 1, 2023.